Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy
Biotech
UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss
Taiho said both cohorts of the trial have been discontinued and that it is considering all possibilities regarding the future of TAS-205.
Gabrielle Masson
Jul 8, 2025 10:17am
Fierce Pharma
2nd patient dies after Sarepta's DMD gene therapy Elevidys
Jun 16, 2025 10:58am
What were the biggest clinical trial flops of 2024?
Feb 21, 2025 9:00am
Solid soars as early DMD gene therapy data beat expectations
Feb 18, 2025 8:10am
Regenxbio starts pivotal study for DMD gene therapy
Nov 18, 2024 2:24pm
DMD gene therapy uses cells to stitch together mRNA in mice
Nov 14, 2024 3:10pm